| DOI | Resolve DOI: https://doi.org/10.1016/S0959-8049(16)32910-0 |
|---|
| Author | Search for: O'connor-mccourt, M.; Search for: Lenferink, A.1; Search for: Zwaagstra, J.1; Search for: Sulea, T.1; Search for: Weeratna, R.1; Search for: Maleki, S.; Search for: Baardsnes, J.1; Search for: Collins, C.1; Search for: Cantin, C.1; Search for: Durocher, Y.1; Search for: Singh, R.1; Search for: Figueredo, R.; Search for: Krishnan, L.1; Search for: Koropatnick, J.; Search for: Tikhomirov, I. |
|---|
| Name affiliation | - National Research Council of Canada. Human Health Therapeutics
|
|---|
| Format | Text, Article |
|---|
| Abstract | In efficacy studies using the syngeneic 4T1 TNBC model, AVID200 was shown to promote significant T-cell infiltration into tumors. This infiltration resulted in reduced primary tumor growth as well as significant reductions in metastatic lesions. Additionally, ex vivo studies revealed that AVID200 treatment decreased T-cell apoptosis, promoted T-cell proliferation in response to tumor cell lysates in the presence of dendritic cells, as well as increased the capacity of T-cells to specifically lyse 4T1 tumor cells. The novel computational design of AVID200 results in a trap with low pM in vitro neutralization potency for TGF-b 1 and 3. Additionally, AVID200 markedly promotes the “T-cell-inflamed” tumor state in vivo. Combination studies with immune checkpoint inhibitors will be presented. |
|---|
| Publication date | 2016-12 |
|---|
| In | |
|---|
| Note | 28 EORTC – NCI – AACR Symposium on Molecular Targets and Cancer Therapeutics Wednesday 29 November 2016: Poster Sessions: Immunotherapy: Poster (Board P144) |
|---|
| Language | English |
|---|
| Peer reviewed | Yes |
|---|
| NPARC number | 23001208 |
|---|
| Export citation | Export as RIS |
|---|
| Report a correction | Report a correction |
|---|
| Record identifier | fc21b4ce-4778-42e5-9a89-dade828fc71b |
|---|
| Record created | 2017-01-05 |
|---|
| Record modified | 2020-03-16 |
|---|
